Bimekizumab
Appearance
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized |
Target | IL17a, IL17f |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
UNII | |
KEGG |
Bimekizumab (INN[1]) is a humanized anti-IL17A and IL-17F monoclonal antibody[2] that is being investigated for ankylosing spondylitis, psoriatic arthritis, and psoriasis.
This drug is being developed by Belgian pharmaceutical UCB. As of 2018[update], bimekizumab is undergoing Phase III trials.
References
- ^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
- ^ Lim SY, Oon HH (2019-05-13). "Systematic review of immunomodulatory therapies for hidradenitis suppurativa". Biologics. 13: 53–78. doi:10.2147/BTT.S199862. PMC 6526329. PMID 31190730.
{{cite journal}}
: CS1 maint: unflagged free DOI (link)